| Detailed information |
|---|
| CancerLivER ID | 2234 |
| Biomarker | CCAT2 |
| Biomarker Name/Symbol (given in Publication) | CCAT2 |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | CCAT2 may be a prognostic biomarker and therapeutic target for HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s Normal; associated with poor survival in HCC patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 28280353 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 96 Paired HCC and non-tumor HCC tissue samples were obtained from 96 patients ; HCC cell lines HepG2, SMMC772 and MHCC97H and the normal liver cell line MIHA |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |